{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:26:16Z","timestamp":1789579576439,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001027","name":"Australian Government Department of Health and Ageing","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001027","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Approximately 10% of people with HIV in Australia had active hepatitis C virus (HCV) infection prior to availability of government-subsidized direct-acting antiviral (DAA) therapy in 2016. This analysis evaluated progress toward HCV elimination among people with HIV in Australia between 2014 and 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The CEASE cohort study enrolled adults with HIV with past or current HCV infection (anti-HCV antibody positive) from 14 primary and tertiary clinics. Biobehavioral, clinical, and virologic data were collected at enrollment (2014\u20132016), follow-up 1 (2017\u20132018), and follow-up 2 (2021\u20132023). HCV treatment uptake, outcome, and HCV RNA prevalence (current infection) were evaluated. Death and HCV reinfection incidence and risk were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 402 participants, 341 (85%) had current HCV infection (RNA positive) at enrollment. Among the sample, 83% were gay and bisexual men, 13% had cirrhosis, and 80% had a history of injecting drug use (42%, past 6 months). DAA treatment was scaled up rapidly, with cumulative treatment uptake increasing from 12% in 2014 to 2015 to 92% in 2022 to 2023. HCV RNA prevalence declined from 85% (95% CI, 81%\u201388%) at enrollment (2014\u20132016) to 8% (95% CI, 6%\u201312%) at follow-up 1 (2017\u20132018) and 0.5% (95% CI, 0%\u20133%) at follow-up 2 (2020\u20132023). Sixteen reinfections occurred (incidence, 1.41 per 100 person-years; 95% CI, .81\u20132.29) as well as 30 deaths (incidence, 1.64 per 100 person-years; 95% CI, 1.11\u20132.34). HCV reinfection incidence declined over time while mortality remained stable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Universal access and rapid DAA uptake were associated with a dramatic reduction in HCV prevalence and reinfection incidence among people with HIV to levels consistent with microelimination.<\/jats:p>\n                  <jats:p>Registration: NCT02102451 (ClinicalTrials.gov).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae665","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T13:01:58Z","timestamp":1734440518000},"source":"Crossref","is-referenced-by-count":7,"title":["Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014\u20132023)"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-0186","authenticated-orcid":false,"given":"Marianne","family":"Martinello","sequence":"first","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney ,","place":["Australia"]},{"name":"Prince of Wales Hospital , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8043-0200","authenticated-orcid":false,"given":"Joanne M","family":"Carson","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1475-9272","authenticated-orcid":false,"given":"Jeffrey J","family":"Post","sequence":"additional","affiliation":[{"name":"Prince of Wales Hospital , Sydney ,","place":["Australia"]},{"name":"The Albion Centre , Sydney ,","place":["Australia"]},{"name":"School of Clinical Medicine, University of New South Wales , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Finlayson","sequence":"additional","affiliation":[{"name":"Taylor Square Private Clinic , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[{"name":"East Sydney Doctors , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-3777","authenticated-orcid":false,"given":"Phillip","family":"Read","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney ,","place":["Australia"]},{"name":"Kirketon Road Clinic , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shaw","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital , Adelaide ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bloch","sequence":"additional","affiliation":[{"name":"Holdsworth House Medical Practice , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Doyle","sequence":"additional","affiliation":[{"name":"Alfred Hospital , Melbourne ,","place":["Australia"]},{"name":"Burnet Institute , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[{"name":"Alfred Hospital , Melbourne ,","place":["Australia"]},{"name":"Burnet Institute , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecaterina","family":"Filep","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Hosseini-Hooshyar","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Dore","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney ,","place":["Australia"]},{"name":"St Vincent's Hospital , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V","family":"Matthews","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney ,","place":["Australia"]},{"name":"St Vincent's Hospital , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"2024122308175874100_ofae665-B1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"key":"2024122308175874100_ofae665-B2","volume-title":"Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030","author":"World Health Organization","year":"2022"},{"key":"2024122308175874100_ofae665-B3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024122308175874100_ofae665-B4","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2468-2667(16)30020-2","article-title":"Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort","volume":"2","author":"Croxford","year":"2017","journal-title":"Lancet Public Health"},{"key":"2024122308175874100_ofae665-B5","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3018(23)00272-2","article-title":"Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies","volume":"11","author":"Trickey","year":"2024","journal-title":"Lancet HIV"},{"key":"2024122308175874100_ofae665-B6","volume-title":"HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2017","author":"Kirby Institute","year":"2017"},{"key":"2024122308175874100_ofae665-B7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1071\/SH16151","article-title":"Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV observational database","volume":"14","author":"Puhr","year":"2017","journal-title":"Sex Health"},{"key":"2024122308175874100_ofae665-B8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jvh.12852","article-title":"Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia","volume":"25","author":"Hajarizadeh","year":"2018","journal-title":"J Viral Hepat"},{"key":"2024122308175874100_ofae665-B9","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","article-title":"Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review","volume":"5","author":"Larney","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2024122308175874100_ofae665-B10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/cid\/ciz985","article-title":"Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in Australia: the CEASE study","volume":"71","author":"Martinello","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024122308175874100_ofae665-B11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3390\/make1030058","article-title":"Introduction to survival analysis in practice","volume":"1","author":"Emmert-Streib","year":"2019","journal-title":"Mach Learn Knowl Extr"},{"key":"2024122308175874100_ofae665-B12","volume-title":"RStudio: integrated development environment for R.","author":"Posit Team","year":"2023"},{"key":"2024122308175874100_ofae665-B13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S2468-1253(21)00077-7","article-title":"Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study","volume":"6","author":"Hajarizadeh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122308175874100_ofae665-B14","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/hep.32002","article-title":"Evaluating the prevention benefit of HCV treatment: modeling the SToP-C treatment as prevention study in prisons","volume":"74","author":"Lim","year":"2021","journal-title":"Hepatology"},{"key":"2024122308175874100_ofae665-B15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/add.14830","article-title":"Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study","volume":"115","author":"Breta\u00f1a","year":"2020","journal-title":"Addiction"},{"key":"2024122308175874100_ofae665-B16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(17)30676-X","article-title":"Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study","volume":"18","author":"Zelenev","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024122308175874100_ofae665-B17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/liv.13528","article-title":"Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study","volume":"38","author":"Beguelin","year":"2018","journal-title":"Liver Int"},{"key":"2024122308175874100_ofae665-B18","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/cid\/cix1007","article-title":"Declining HCV incidence in Dutch HIV positive men who have sex with men after unrestricted access to HCV therapy","volume":"66","author":"Boerekamps","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024122308175874100_ofae665-B19","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/cid\/cix1004","article-title":"High treatment uptake in human immunodeficiency virus\/hepatitis C virus\u2013coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands","volume":"66","author":"Boerekamps","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024122308175874100_ofae665-B20","doi-asserted-by":"crossref","first-page":"ofx258","DOI":"10.1093\/ofid\/ofx258","article-title":"Human immunodeficiency virus\/hepatits C virus coinfection in Spain: elimination is feasible, but the burden of residual cirrhosis will be significant","volume":"5","author":"Berenguer","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2024122308175874100_ofae665-B21","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/QAD.0000000000001789","article-title":"Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV","volume":"32","author":"Pradat","year":"2018","journal-title":"AIDS"},{"key":"2024122308175874100_ofae665-B22","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/cid\/ciaa645","article-title":"Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: a longitudinal analysis","volume":"73","author":"Newsum","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024122308175874100_ofae665-B23","doi-asserted-by":"crossref","first-page":"e26168","DOI":"10.1002\/jia2.26168","article-title":"Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study","volume":"26","author":"Carson","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"2024122308175874100_ofae665-B24","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/cid\/ciac246","article-title":"Hepatitis C virus reinfection following direct-acting antiviral treatment in the prison setting: the SToP-C study","volume":"75","author":"Carson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024122308175874100_ofae665-B25","doi-asserted-by":"crossref","first-page":"e25219","DOI":"10.1002\/jia2.25219","article-title":"Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific","volume":"22","author":"Jung","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"2024122308175874100_ofae665-B26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.30412","article-title":"Management of sepsis in patients with cirrhosis: current evidence and practical approach","volume":"70","author":"Simonetto","year":"2019","journal-title":"Hepatology"},{"key":"2024122308175874100_ofae665-B27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"2024122308175874100_ofae665-B28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jclinepi.2018.04.015","article-title":"National characteristics and trends in antiretroviral treatment in Australia can be accurately estimated using a large clinical cohort","volume":"100","author":"Huang","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2024122308175874100_ofae665-B29","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3018(18)30072-9","article-title":"Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013\u201317","volume":"5","author":"Holt","year":"2018","journal-title":"Lancet HIV"},{"key":"2024122308175874100_ofae665-B30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QAI.0000000000003224","article-title":"Changing characteristics of HIV-positive gay and bisexual men's relationships in the era of biomedical prevention","volume":"94","author":"Broady","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024122308175874100_ofae665-B31","doi-asserted-by":"crossref","first-page":"e2164","DOI":"10.1093\/cid\/ciaa1500","article-title":"Microelimination of hepatitis C among people with human immunodeficiency virus coinfection: declining incidence and prevalence accompanying a multicenter treatment scale-up trial","volume":"73","author":"Doyle","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024122308175874100_ofae665-B32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10461-022-03788-1","article-title":"Adjusting behavioural surveillance and assessing disparities in the impact of COVID-19 on gay and bisexual men's HIV-related behaviour in Australia","volume":"27","author":"Holt","year":"2023","journal-title":"AIDS Behav"},{"key":"2024122308175874100_ofae665-B33","volume-title":"HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2023","author":"King","year":"2023"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/12\/ofae665\/61136743\/ofae665.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/12\/ofae665\/61136743\/ofae665.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T08:18:18Z","timestamp":1734941898000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae665\/7918128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae665","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,11,27]]},"article-number":"ofae665"}}